Clinical Trial

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-05-09; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2023-07-18
Trial Details
NCT Number NCT05865535
Lead Sponsor AVEO Pharmaceuticals, Inc.
Conditions Cachexia
Enrollment 30 participants
Start Date 2023-06-13
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-08